GENE THERAPY, OPEN-LABEL, DOSE-ESCALATION STUDY OF SPK-9001 (ADENO-ASSOCIATED VIRAL VECTOR WITH HUMAN FACTOR IX GENE) IN SUBJECTS WITH HEMOPHILIA B
- Registry ID
- SPK-9001-101
- Source registry
- HEALTH_CANADA
- Status
- Ongoing
- Study type
- INTERVENTIONAL
- Sponsor
- SPARK THERAPEUTICS INC
- Start date
- 2016-12-09
- Last update
- 2016-07-22
Conditions
Related clinical trials
- AN OPEN-LABEL, PARALLEL, PHASE 3, TWO-ARM STUDY TO INVESTIGATE THE EFFICACY AND
SAFETY OF FITUSIRAN PROPHYLAXIS IN MALE PARTICIPANTS AGED 1 TO LESS THAN 12 YEARS
WITH HEMOPHILIA A OR B WITH OR WITHOUT INHIBITORY ANTIBODIES TO FACTORS VIII OR IX
- A TWO-PART OPEN-LABEL STUDY OF REGV131-LNP1265, A CRISPR/CAS9-BASED
COAGULATION FACTOR IX GENE INSERTION THERAPY IN PARTICIPANTS WITH HEMOPHILIA B
- PHASE 3B, OPEN-LABEL, MULTICENTER, SINGLE-DOSE STUDY INVESTIGATING EFFICACY AND SAFETY OF CSL222 (ETRANACOGENE DEZAPARVOVEC) GENE THERAPY ADMINISTERED TO ADULT SUBJECTS WITH SEVERE OR MODERATELY SEVERE HEMOPHILIA B WITH DETECTABLE PRETREATMENT AAV5 NEUTRALIZING ANTIBODIES
- A GLOBAL, OPEN-LABEL, ADAPTIVE DESIGN STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF SERPINPC IN SUBJECTS WITH SEVERE HEMOPHILIA A OR MODERATELY SEVERE TO SEVERE HEMOPHILIA B
- A PHASE 3, SINGLE-ARM, MULTICENTER, MULTINATIONAL, OPEN-LABEL, ONE-WAY CROSSOVER STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF FITUSIRAN PROPHYLAXIS IN MALE PARTICIPANTS AGED >/= 12 YEARS WITH SEVERE HEMOPHILIA A OR B, WITH OR WITHOUT INHIBITORY ANTIBODIES TO FACTOR VIII OR IX
- AN OPEN-LABEL EXTENSION STUDY TO EVALUATE THE LONG-TERM SAFETY, TOLERABILITY, AND EFFICACY OF MARSTACIMAB PROPHYLAXIS IN SEVERE (COAGULATION FACTOR ACTIVITY <1%) HEMOPHILIA A PARTICIPANTS WITH OR WITHOUT INHIBITORS OR MODERATELY SEVERE TO SEVERE HEMOPHILIA B PARTICIPANTS (COAGULATION FACTOR ACTIVITY <=2%) WITH OR WITHOUT INHIBITORS
View on source registry